Gene Name |
Gene ID |
KEGG ID |
Pathway Name |
EC No. |
BRAF | 673 | hsa04010 | MAPK signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04012 | ErbB signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04062 | Chemokine signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04150 | mTOR signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04270 | Vascular smooth muscle contraction   | 2.7.11.1 |
BRAF | 673 | hsa04510 | Focal adhesion   | 2.7.11.1 |
BRAF | 673 | hsa04650 | Natural killer cell mediated cytotoxicity   | 2.7.11.1 |
BRAF | 673 | hsa04720 | Long-term potentiation   | 2.7.11.1 |
BRAF | 673 | hsa04722 | Neurotrophin signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04730 | Long-term depression   | 2.7.11.1 |
BRAF | 673 | hsa04810 | Regulation of actin cytoskeleton   | 2.7.11.1 |
BRAF | 673 | hsa04910 | Insulin signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04914 | Progesterone-mediated oocyte maturation   | 2.7.11.1 |
BRAF | 673 | hsa05160 | Hepatitis C   | 2.7.11.1 |
BRAF | 673 | hsa05200 | Pathways in cancer   | 2.7.11.1 |
BRAF | 673 | hsa05210 | Colorectal cancer   | 2.7.11.1 |
BRAF | 673 | hsa05211 | Renal cell carcinoma   | 2.7.11.1 |
BRAF | 673 | hsa05212 | Pancreatic cancer   | 2.7.11.1 |
BRAF | 673 | hsa05213 | Endometrial cancer   | 2.7.11.1 |
BRAF | 673 | hsa05214 | Glioma   | 2.7.11.1 |
BRAF | 673 | hsa05215 | Prostate cancer   | 2.7.11.1 |
BRAF | 673 | hsa05216 | Thyroid cancer   | 2.7.11.1 |
BRAF | 673 | hsa05218 | Melanoma   | 2.7.11.1 |
BRAF | 673 | hsa05219 | Bladder cancer   | 2.7.11.1 |
BRAF | 673 | hsa05220 | Chronic myeloid leukemia   | 2.7.11.1 |
BRAF | 673 | hsa05221 | Acute myeloid leukemia   | 2.7.11.1 |
BRAF | 673 | hsa05223 | Non-small cell lung cancer   | 2.7.11.1 |
BRAF | 673 | hsa04010 | MAPK signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04012 | ErbB signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04062 | Chemokine signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04150 | mTOR signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04270 | Vascular smooth muscle contraction   | 2.7.11.1 |
BRAF | 673 | hsa04510 | Focal adhesion   | 2.7.11.1 |
BRAF | 673 | hsa04650 | Natural killer cell mediated cytotoxicity   | 2.7.11.1 |
BRAF | 673 | hsa04720 | Long-term potentiation   | 2.7.11.1 |
BRAF | 673 | hsa04722 | Neurotrophin signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04730 | Long-term depression   | 2.7.11.1 |
BRAF | 673 | hsa04810 | Regulation of actin cytoskeleton   | 2.7.11.1 |
BRAF | 673 | hsa04910 | Insulin signaling pathway   | 2.7.11.1 |
BRAF | 673 | hsa04914 | Progesterone-mediated oocyte maturation   | 2.7.11.1 |
BRAF | 673 | hsa05160 | Hepatitis C   | 2.7.11.1 |
BRAF | 673 | hsa05200 | Pathways in cancer   | 2.7.11.1 |
BRAF | 673 | hsa05210 | Colorectal cancer   | 2.7.11.1 |
BRAF | 673 | hsa05211 | Renal cell carcinoma   | 2.7.11.1 |
BRAF | 673 | hsa05212 | Pancreatic cancer   | 2.7.11.1 |
BRAF | 673 | hsa05213 | Endometrial cancer   | 2.7.11.1 |
BRAF | 673 | hsa05214 | Glioma   | 2.7.11.1 |
BRAF | 673 | hsa05215 | Prostate cancer   | 2.7.11.1 |
BRAF | 673 | hsa05216 | Thyroid cancer   | 2.7.11.1 |
BRAF | 673 | hsa05218 | Melanoma   | 2.7.11.1 |
BRAF | 673 | hsa05219 | Bladder cancer   | 2.7.11.1 |
BRAF | 673 | hsa05220 | Chronic myeloid leukemia   | 2.7.11.1 |
BRAF | 673 | hsa05221 | Acute myeloid leukemia   | 2.7.11.1 |
BRAF | 673 | hsa05223 | Non-small cell lung cancer   | 2.7.11.1 |